Skip to main content
. 2021 Jul 14;10(14):3106. doi: 10.3390/jcm10143106

Table 2.

Disease onset and visual problems.

Cohort 1-1
(Discontinued Due to the Doctor’s
Decision)
Cohort 1-2
(Discontinued Due to Their Own
Decision)
Cohort 2
(Continuing
Treatment)
n 185 22 65
Diagnosis
Within 1 year 2 (1.1) 0 6 (9.2)
Within 3 years 55 (29.7) 4 (18.2) 23 (35.4)
Within 5 years 59 (31.9) 7 (31.8) 16 (24.6)
Within 10 years 47 (25.4) 5 (22.7) 13 (20.0)
More than 10 years 22 (11.9) 6 (27.3) 7 (10.8)
Number of affected eyes
One 166 (89.7) 21 (95.5) 56 (86.2)
Both 19 (10.3) 1 (4.5) 9 (13.8)
Current BCVA of the affected eye (self-reported)
0.01–0.1 (20/2000 to 20/200) 44 (23.8) 4 (18.2) 9 (13.8)
0.2–0.3 (20/100 to 20/67) 26 (14.1) 4 (18.2) 11 (16.9)
0.4–0.6 (20/50 to 20/33) 39 (21.1) 5 (22.7) 22 (33.8)
0.7–1.0 (20/29 to 20/20) 53 (28.6) 6 (27.3) 11 (16.9)
≥1.2 (≥20/17) 12 (6.5) 2 (9.1) 8 (12.3)
Not sure 11 (5.9) 1 (4.5) 4 (6.2)
Difficulties in daily life
Recognizing faces or objects 21 (11.4) 4 (18.2) 8 (12.3)
Reading books or newspapers 72 (38.9) 13 (59.1) 20 (30.8)
Driving 33 (17.8) 6 (27.3) 15 (23.1)
Going out alone 2 (1.1) 0 3 (4.6)
Other 21 (11.4) 2 (9.1) 7 (10.8)
No particular difficulties 81 (43.8) 3 (13.6) 30 (46.2)

Values are n (%); BCVA, best-corrected visual acuity.